

## SEPTEMBER

Date	Headline and Source	Link	Summary
1 <sup>st</sup> September	HCMCT Manipal Hospital, Dwarka, Pfizer join hands to launch Centre of Excellence for Adult Vaccination Medical Dialogues, September 01, 2024	<a href="#">HCMCT Manipal Hospital, Dwarka, Pfizer join hands to launch Centre of Excellence for Adult Vaccination</a>	In a country where vaccination is often associated only with childhood immunisation and the need for adult vaccines is often overlooked, HCMCT Manipal Hospital and Pfizer India have collaborated to launch a dedicated Centre for adult vaccination at HCMCT Manipal Hospital, Dwarka, New Delhi, strengthening the delivery of adult vaccines.
3 <sup>rd</sup> September	Alkem inks licensing pact with Takeda to introduce Vonoprazan in India The Economic Times, September 03, 2024	<a href="#">Alkem inks licensing pact with Takeda to introduce Vonoprazan in India</a>	The company has a formidable presence in the gastrointestinal segment and this non-exclusive patent licence with Takeda will help us offer a product with novel mechanism of action for a large number of patients in India who are suffering from gastro-related ailments," Alkem Laboratories CEO Vikas Gupta said in a statement.
3 <sup>rd</sup> September	How AbbVie Catapults career development using the 3-track path Hrkatha, September 03, 2024	<a href="#">How AbbVie Catapults career development using the 3-track path</a>	In the pharmaceutical industry, career development often follows a linear path, limiting options for employees seeking broader growth. Recognising this gap, AbbVie, a global biopharmaceutical company, introduced the Catapult programme, a tailored initiative designed to offer employees opportunities beyond traditional trajectories, such as roles in marketing, business analytics, and sales training.
3 <sup>rd</sup> September	Pfizer gets CDSCO Panel nod to import, and market Aztreonam plus Avibactam Powder Medical Dialogues, September 03, 2024	<a href="#">Pfizer gets CDSCO Panel nod to import, and market Aztreonam plus Avibactam Powder</a>	The drug major Pfizer has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to import and market the antimicrobial fixed-dose combination (FDC) of Aztreonam 1.5 gm plus Avibactam 0.5gm powder for concentrate for solution for infusion with the condition to conduct the Phase IV clinical trial.
4 <sup>th</sup> September	Making sustainability sustainable Express Pharma, September 04, 2024	<a href="#">Making sustainability sustainable</a>	Anil Matai, Director General, Organisation of Pharmaceutical Producers of India (OPPI), which represents India subsidiaries of MNC pharma companies, believes that true sustainability involves adopting a long-term perspective that

			prioritises the wellbeing of both the people and the planet.
4 <sup>th</sup> September	Vizag gets a centre of excellence for adult vaccination The Times of India, September 04, 2024	<a href="#">Vizag gets a centre of excellence for adult vaccination</a>	Pfizer India and Apollo Hospitals have jointly established a new dedicated Centre of Excellence (CoE) for adult vaccination at Apollo Hospital, Visakhapatnam. The CoE aims to strengthen communitywide protection against various vaccine-preventable diseases such as pneumococcal disease, influenza, human papillomavirus, and hepatitis A and B, among others
4 <sup>th</sup> September	Alkem Laboratories Partners with Takeda to Launch Vonoprazan for Gastroesophageal Reflux Disease in India E Health, September 04, 2024	<a href="#">Alkem Laboratories Partners with Takeda to Launch Vonoprazan for Gastroesophageal Reflux Disease in India</a>	Alkem Laboratories Ltd. (BSE: 539523, NSE: ALKEM), a prominent Indian pharmaceutical company has announced a strategic non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Ltd., aimed at introducing Vonoprazan in the Indian market under the brand name "Vonzai." This collaboration marks a significant step forward in the treatment of Gastroesophageal Reflux Disease (GERD) and related disorders.
6 <sup>th</sup> September	CDSCO Panel Approves AstraZeneca's Protocol Amendment proposal for COPD drug Tozorakimab Medical Dialogues, September 06, 2024	<a href="#">CDSCO Panel Approves AstraZeneca's Protocol Amendment proposal for COPD drug Tozorakimab</a>	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the clinical trial protocol amendment proposal of the drug major AstraZeneca Pharma India to study the long-term efficacy and safety of Tozorakimab in participants with chronic obstructive pulmonary disease with a history of exacerbation.
8 <sup>th</sup> September	CDSCO Panel Approves Sanofi's Protocol Amendment proposal for Fitusiran study Medical Dialogues, September 08, 2024	<a href="#">CDSCO Panel Approves Sanofi's Protocol Amendment proposal for Fitusiran study</a>	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major Sanofi's protocol amendment proposal of the clinical trial titled "A Phase 3, single-arm, multi-center, multinational, open label, one-way crossover study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged = 12 years with severe hemophilia A or B, with or without inhibitory antibodies to factor VIII or IX".
10 <sup>th</sup> September	Lung Cancer Research Foundation announces new research collaboration with Bayer Pharma The Financial Express, September 10, 2024	<a href="#">Lung Cancer Research Foundation announces new research collaboration with Bayer Pharma</a>	The Lung Cancer Research Foundation (LCRF) on Monday announced its collaboration with Bayer Pharmaceuticals to fund two research grants focused on innovative strategies to advance understanding and management of lung

			cancers harbouring HER2 mutations and/or other HER2 alterations.
10 <sup>th</sup> September	Boehringer Ingelheim announces plans to advance potential new treatment for geographic atrophy The Financial Express, September 10, 2024	<a href="#">Boehringer Ingelheim announces plans to advance potential new treatment for geographic atrophy</a>	Boehringer Ingelheim and CDRLife on Monday announced positive results from the phase I trial of an investigational antibody fragment developed to preserve vision in people living with geographic atrophy (GA). According to the company's statement, BI 771716 met its primary safety endpoint following intravitreal administration of single and multiple doses.
11 <sup>th</sup> September	GST cut on key cancer drugs set to boost patient coverage, say experts Business Standard, September 11, 2024	<a href="#">GST cut on key cancer drugs set to boost patient coverage, say experts</a>	"We recommend extending these exemptions not only to all cancer medications but also to all rare disease medications. Such initiatives will make a significant difference in the lives of patients across India, enabling better treatment and improving overall health care outcomes," said Anil Matai, director general of the Organisation of Pharmaceutical Producers of India, which represents multinational drug firms in India.
12 <sup>th</sup> September	Stakeholders welcome govt's decision to slash GST rate on cancer drugs from 12% to 5% Bio Voice News, September 12, 2024	<a href="#">Stakeholders welcome govt's decision to slash GST rate on cancer drugs from 12% to 5%</a>	Welcoming the move, Anil Matai, Director General, OPPI said: "We commend the Government's decision to reduce the GST rate on certain cancer drugs from 12% to 5%. This reduction marks a pivotal step in making life-saving treatments more affordable and accessible. We at the Organisation of Pharmaceutical Producers of India (OPPI) applaud this decision by the GST Council.
12 <sup>th</sup> September	Months after import duty waiver, GST slashed on same 3 anticancer drugs. Why this is little relief The Print, September 12, 2024	<a href="#">Months after import duty waiver, GST slashed on same 3 anticancer drugs. Why this is little relief</a>	The anticancer medicines on which the government has offered BCD concession and now GST reduction include immune and targeted therapies such as trastuzumab deruxtecan, osimertinib, and durvalumaball three by British-Swedish pharma giant AstraZeneca.
13 <sup>th</sup> September	7 In 10 Indians Support Health Coverage Expansion For Senior Citizens, Poll Reveals NDTV, September 13, 2024	<a href="#">7 In 10 Indians Support Health Coverage Expansion For Senior Citizens, Poll Reveals</a>	It is a significant milestone in providing essential healthcare services to the elderly, said Anil Matai, Director General, Organisation of Pharmaceutical Producers of India (OPPI). As our elderly population grows, so does the need for specialised geriatric care, and this expansion will enable more families to access essential services without the burden of overwhelming medical expenses, added

			Dr. Harsh Mahajan, President FICCI (Health Services).
14 <sup>th</sup> September	Poll: 7 in 10 Indians support health cover for those over 70 Health Dialogues, September 14, 2024	<a href="#">Poll: 7 in 10 Indians support health cover for those over 70</a>	It is a significant milestone in providing essential healthcare services to the elderly, said Anil Matai, Director General, Organisation of Pharmaceutical Producers of India (OPPI). As our elderly population grows, so does the need for specialised geriatric care, and this expansion will enable more families to access essential services without the burden of overwhelming medical expenses, added Dr. Harsh Mahajan, President FICCI (Health Services).
14 <sup>th</sup> September	Free health treatment: Free treatment up to Rs 5 lakh for people above 70 years of age, 5 out of 7 Indians are happy Patrika, September 14, 2024	<a href="#">Free health treatment: Free treatment up to Rs 5 lakh for people above 70 years of age, 5 out of 7 Indians are happy</a>	Experts opinion Industry experts also praised the government's decision. Anil Matai, director general of the Organization for Pharmaceutical Production (OPPI), called it an important milestone in providing essential healthcare services to the elderly.
14 <sup>th</sup> September	CDSCO Approves safety, efficacy data with DMC report for Novartis antimalarial drug Cipargamin Medical Dialogues, September 14, 2024	<a href="#">CDSCO Approves safety, efficacy data with DMC report for Novartis antimalarial drug Cipargamin</a>	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the safety and efficacy data with the DMC (Data Monitoring Committees) report presented by the drug major Novartis for malaria drug Cipargamin (KAE609) study.
15 <sup>th</sup> September	GST slashed on 3 cancer drugs: How will it benefit patients India Today, September 15, 2024	<a href="#">GST slashed on 3 cancer drugs: How will it benefit patients</a>	These anticancer medicines are immune and targeted therapies such as trastuzumab deruxtecan, osimertinib, and durvalumab, sold by British-Swedish pharmaceutical and biotechnology company AstraZeneca.
18 <sup>th</sup> September	Health Coverage for Over 70s Set to Provide Relief for Millions, Say Industry Experts Only My Health, September 18, 2024	<a href="#">Health Coverage for Over 70s Set to Provide Relief for Millions, Say Industry Experts</a>	Anil Matai, Director General of the Organisation of Pharmaceutical Producers of India (OPPI), described the decision as a milestone in improving healthcare services for elderly citizens. According to Matai, the expansion under AB PMJAY represents a crucial step in fostering a more inclusive healthcare ecosystem that accounts for the unique needs of seniors.
21 <sup>st</sup> September	Pfizer to offer fellowships for PhD scholars The Hans India, September 21, 2024	<a href="#">Pfizer to offer fellowships for PhD scholars</a>	In a major boost to academic research, GITAM and Pfizer Healthcare India Private Limited, Visakhapatnam entered into a memorandum of understanding (MoU) to support research excellence. As part of this collaboration, Pfizer Healthcare India will provide educational grants in the form

			of fellowships for the institution's PhD scholars.
21 <sup>st</sup> September	Abbott India joins hand with Takeda Pharma to launch Vonoprazan tablets in India Business Standard, September 21, 2024	<a href="#">Abbott India joins hand with Takeda Pharma to launch Vonoprazan tablets in India</a>	Abbott India said that it has signed a nonexclusive patent license agreement with Takeda Pharmaceuticals Company to commercialize Vonoprazan, a novel molecule in the gastrointestinal therapy area, under the brand name Vonefi. Vonoprazan (PCAB or potassium competitive acid blocker) addresses severe acid related disorders like reflux esophagitis through a once daily dose
21 <sup>st</sup> September	AstraZeneca to launch Palivizumab (Synagis) in India Express Pharma, September 21, 2024	<a href="#">AstraZeneca to launch Palivizumab (Synagis) in India</a>	AstraZeneca Pharma India received import and market permission in September 2023, from the Drug Controller General of India (DCGI) for Palivizumab (Synagis) solution for injection 100 mg/ml (rDNA origin) (50mg/0.5mL & 100 mg/mL presentations in single-dose vials administered through intramuscular route).
22 <sup>nd</sup> September	CDSCO Panel Approves Pfizer's Protocol Amendment Proposal to Study Aztreonam and Avibactam Medical Dialogues, September 22, 2024	<a href="#">CDSCO Panel Approves Pfizer's Protocol Amendment Proposal to Study Aztreonam and Avibactam</a>	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol amendment proposal presented by the drug major Pfizer to study Aztreonam and Avibactam compared to the best available therapy for serious gram-negative infections.
22 <sup>nd</sup> September	Novo Nordisk Launches Safe Pharmaceuticals Disposal Initiative For Employees The CSR Universe, September 22, 2024	<a href="#">Novo Nordisk Launches Safe Pharmaceuticals Disposal Initiative For Employees</a>	Global healthcare company Novo Nordisk Global Business Services (GBS) has launched a sustainable initiative aimed at promoting safe and responsible disposal of pharmaceutical products. Launched internally for employees in partnership with Connect and Heal Foundation, Eco Med Safe program is designed to minimise environmental impact and enhance public health by safely disposing unused or expired medicines.
24 <sup>th</sup> September	Pfizer launches company's first ever dedicated commercial analytics centre in India BioSpectrum India, September 24, 2024	<a href="#">Pfizer launches company's first ever dedicated commercial analytics centre in India</a>	The Analytics Gateway represents a significant milestone in Pfizer's international commercial strategy and is positioned to be a global capability centre serving all of Pfizer's international (ex-US) markets to bring analytics, and insight breakthroughs that will benefit patients.
24 <sup>th</sup> September	Sight-savers India and AbbVie India hosts third state-level consultation on Glaucoma prevention in Bhopal	<a href="#">Sight-savers India and AbbVie India hosts third state-level consultation on Glaucoma prevention in Bhopal</a>	The third state-level consultation in the ongoing collaborative campaign between Sight-savers India and AbbVie India was successfully held at Hotel Palaash

	Media Brief, September 24, 2024		Residency, focusing on strategies to prevent visual impairment due to glaucoma.
25 <sup>th</sup> September	AstraZeneca India gets CDSCO nod for its chemotherapy drug additional indications The Financial Express, September 25, 2024	<a href="#">AstraZeneca India gets CDSCO nod for its chemotherapy drug additional indications</a>	AstraZeneca Pharma India Limited on Monday announced that has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion from the Central Drugs Standard Control Organisation (CDSCO).
25 <sup>th</sup> September	AstraZeneca Pharma receives nod for cancer drug Durvalumab; stock soars 12% Business Standard, September 25, 2024	<a href="#">AstraZeneca Pharma receives nod for cancer drug Durvalumab; stock soars 12%</a>	Stocks of pharmaceutical company AstraZeneca Pharma were buzzing in trade on Tuesday, September 24, 2024. The stock of AstraZeneca surged up to 11.90 per cent to hit an intraday high of Rs 7,549.95 per share. Meanwhile, the stock's 52-week high is 7,550 per share.
25 <sup>th</sup> September	Eli Lilly planning expansion of research centre in India: CEO David Ricks Medical Dialogues, September 25, 2024	<a href="#">Eli Lilly planning expansion of research centre in India: CEO David Ricks</a>	Eli Lilly is planning the expansion of its research centre in India and will be partnering with other Indian companies. Eli Lilly CEO David Ricks highlighted this after a roundtable interaction with PM Narendra Modi in New York. We have already a large research-based centre in India.
26 <sup>th</sup> September	AstraZeneca gets nod to launch cancer drug The Times of India, September 26, 2024	<a href="#">AstraZeneca gets nod to launch cancer drug</a>	AstraZeneca Pharma India has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion from the Central Drugs Standard Control Organisation (CDSCO), subject to the receipt of related statutory approvals.
26 <sup>th</sup> September	Bhopal hosts state-level consultation on glaucoma prevention health care radius, September 26, 2024	<a href="#">Bhopal hosts state-level consultation on glaucoma prevention</a>	The third Madhya Pradesh state-level consultation in the ongoing collaborative campaign by Sight-savers India, an organization devoted to eye health; and AbbVie India, an eye care product company, was held recently in Bhopal, focusing on strategies to prevent visual impairment due to glaucoma.
27 <sup>th</sup> September	Bhushan Akshikar appointed as President of OPPI The Financial Express, September 27, 2024	<a href="#">Bhushan Akshikar appointed as President of OPPI</a>	The Organisation of Pharmaceutical Producers of India (OPPI) on Thursday announced that it has appointed Bhushan Akshikar as its President for a term of two years effective 26th September 2024. According to the organisation, Bhushan is a seasoned business leader and has an experience of over 13 years in key leadership roles in GSK across India, Middle East, Russia CIS & Africa region.

28 <sup>th</sup> September	OPPI appoints GSK-chief as new president The Hindu Business Line, September 28, 2024	<a href="#">OPPI appoints GSK-chief as new president</a>	The Organisation of Pharmaceutical Producers of India (OPPI) has appointed GlaxoSmithKline Pharmaceuticals Managing Director Bhushan Akshikar as its President, for two years from September 26, 2024. Bhushan has over 13 years' experience in key leadership roles in GSK across India, Middle East, Russia CIS & Africa region.
----------------------------	--	--	--

---